

## Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease

Hutchison, Colin A; Burmeister, Anne; Harding, Stephen J; Basnayake, Kolitha; Church, Hannah; Jesky, Mark D; White, Katie; Green, Clara E; Stringer, Stephanie J; Bassett, Paul; Ferro, Charles J; Cockwell, Paul

DOI:

[10.1016/j.mayocp.2014.01.028](https://doi.org/10.1016/j.mayocp.2014.01.028)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Hutchison, CA, Burmeister, A, Harding, SJ, Basnayake, K, Church, H, Jesky, MD, White, K, Green, CE, Stringer, SJ, Bassett, P, Ferro, CJ & Cockwell, P 2014, 'Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease', *Mayo Clinic Proceedings*, vol. 89, no. 5, pp. 615-622.  
<https://doi.org/10.1016/j.mayocp.2014.01.028>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

<https://doi.org/10.1016/j.mayocp.2014.01.028>

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# Serum Polyclonal Immunoglobulin Free Light Chain Levels Predict Mortality in People With Chronic Kidney Disease

Colin A. Hutchison, PhD; Anne Burmeister, PhD; Stephen J. Harding, PhD; Kolitha Basnayake, PhD; Hannah Church, MBChB; Mark D. Jesky, MBChB; Katie White, MBChB; Clara E. Green, MBChB; Stephanie J. Stringer, PhD; Paul Bassett, MSc; Charles J. Ferro, MD; and Paul Cockwell, PhD

## Abstract

**Objective:** To determine whether elevated serum polyclonal free light chain (FLC) levels predict mortality in a population of individuals with chronic kidney disease (CKD).

**Patients and Methods:** From January 2, 2006, through July 31, 2007, we recruited a cohort of 848 people with CKD who were not receiving renal replacement therapy and did not have monoclonal gammopathy. We measured serum kappa FLC and lambda FLC isotype levels to determine combined FLC (cFLC) levels. The cohort was prospectively followed up for a median of 63 months (interquartile range, 0-93 months). Cox regression analysis was performed to determine variables predictive of mortality.

**Results:** High cFLC levels were an independent risk factor for death (hazard ratio [HR], 2.71; 95% CI, 1.98-3.70;  $P < .001$ ). Other independent risk factors were age (HR, 1.79; 95% CI, 1.52-2.10;  $P < .001$ ), South Asian ethnicity (HR, 0.33; 95% CI, 0.14-0.64;  $P = .02$ ), preexisting cardiovascular disease (HR, 1.59; 95% CI, 1.09-2.31;  $P = .02$ ), and high-sensitivity C-reactive protein (HR, 1.13; 95% CI, 1.00-1.28;  $P = .04$ ). Neither estimated glomerular filtration rate nor albuminuria was an independent risk factor for death.

**Conclusion:** High cFLC levels independently predict mortality in people with CKD.

© 2014 Mayo Foundation for Medical Education and Research. Open access under CC BY-NC-ND license.

■ Mayo Clin Proc. 2014;89(5):615-622

Chronic kidney disease (CKD) affects more than 10% of the adult population,<sup>1,2</sup> and a high proportion of total health care budgets is used in managing patients with CKD.<sup>3,4</sup> The mortality associated with CKD is high and is related to both baseline kidney function and the rate of progression of CKD.<sup>5,6</sup> The major cause of increased mortality is cardiovascular disease (CVD), although there is also increased mortality from cancer and infections.<sup>7,8</sup>

To better target management in CKD, enhanced risk stratification is required.<sup>1</sup> At present, risk assessment is based on the measurements of kidney function (estimated glomerular filtration rate [eGFR]) and kidney injury (proteinuria). However, as chronic inflammation is an important component of risk in CKD,<sup>9</sup> the serum levels of molecules that are affected by both kidney function and immune/inflammatory status may represent

better tools for risk assessment than do current routine tests.

Immunoglobulin light chains are a component of the intact immunoglobulin molecule produced by plasma cells and other cells of the B-cell lineage. Free light chains (FLCs) are produced in excess during immunoglobulin synthesis and are cleared from the serum by the kidneys; therefore, a decrease in the GFR is associated with an increase in serum FLC levels. An assessment of the ratio of the 2 isotypes of FLC— $\kappa$ FLC and  $\lambda$ FLC—is widely used in the diagnosis and management of plasma cell disorders to identify and quantify monoclonal FLC.<sup>10,11</sup> However, the measurement of serum polyclonal FLC may also identify global immune activation. Recent studies have found an association between increased levels of polyclonal FLC and outcomes in the general population and in people with autoimmune disease, cancer, and kidney disease.<sup>12-18</sup>

From the Hawke's Bay District Health Board, Hawke's Bay, New Zealand (C.A.H.); The Binding Site Group Ltd, Birmingham, United Kingdom (A.B., S.J.H.); Department of Renal Medicine, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham, United Kingdom (A.B., H.C., M.D.J., K.W., C.E.G., S.J.S., C.J.F., P.C.); Division of Immunity and Infection, University of Birmingham, Medical School, Birmingham, United Kingdom (S.J.H., S.J.S., C.J.F., P.C.); Sussex Kidney Unit, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom (K.B.); and Statsconsultancy, Ltd, Amersham, Bucks, United Kingdom (P.B.).

Therefore, the objective of this study was to evaluate the hypothesis that serum levels of polyclonal FLC are predictive of mortality in people with CKD. To address this, we performed a large cohort study of people with CKD (non—renal replacement therapy) incorporating other bioclinical variables of known importance for outcomes.

## PATIENTS AND METHODS

The study was approved by the Solihull and South Birmingham Research Ethics committees (reference number 05/Q2702/50) and the R&D department of University Hospitals Birmingham NHS Foundation Trust. All patients gave informed written consent to participate in the study.

### Study Population

From January 2, 2006, through July 31, 2007, we recruited a cohort (n=916) of patients under follow-up in adult kidney disease clinics at University Hospitals Birmingham. Patients were approached on the basis of the following selection criteria: they fulfilled the K/DOQI criteria for CKD,<sup>19</sup> and they were not receiving renal replacement therapy (through dialysis or a functioning kidney transplant). All patients who fulfilled these criteria and who had an appointment in a clinic attended by the enrolling investigator (C.A.H.) were provided with written information about the study and then approached and asked to provide informed consent for the study. Once the patients were enrolled in the study, the following baseline parameters were collected: age, sex, ethnicity, CVD comorbidity (ischemic heart disease, cardiac failure, cerebrovascular disease, and peripheral vascular disease), diabetes mellitus, blood pressure (BP), medications, urinary albumin/creatinine ratio (ACR), and serum laboratory variables (albumin, phosphate, calcium, creatinine, cystatin C, high-sensitivity C-reactive protein (hsCRP), estimated glomerular filtration rate (eGFR) by the abbreviated modification of diet in renal disease equation (MDRD), and serum FLC. Sixty-eight patients (7.4%) were excluded from the analysis because they had a monoclonal gammopathy of undetermined significance (MGUS) at the time of recruitment. A diagnosis of MGUS is independently associated with an increased mortality<sup>20,21</sup> and

abnormalities in FLC independent of kidney function.<sup>22</sup> Therefore, 848 patients (92.6%) were included in this analysis.

### Laboratory Analysis

Creatinine, albumin, calcium, and phosphate were measured using a Roche Modular Analyser (Roche Diagnostics); the normal ranges were as follows: 50 to 125  $\mu\text{mol/L}$ , 35 to 50 g/L, 2.25 to 2.75 mmol/L, and 0.8 to 1.4 mmol/L, respectively. Urine albumin and creatinine were measured by using automated immunoturbidimetry with antibody against human albumin and a compensated version of the Jaffe reaction (Roche Diagnostics). A normal ACR was defined as less than 2.5 mg/mmol for men and less than 3.5 mg/mmol for women. The results reported for ACR, systolic BP, and diastolic BP are the median of 3 clinic appointments: the recruitment clinic, the clinic before recruitment, and the clinic after recruitment.

To diagnose a MGUS, sera were tested by serum protein electrophoresis (Sebia Hydragel Protein kit on the Hydrasys system, Sebia) and serum FLC immunoassays (Freelite on the Dade-Behring BN II Analyser, The Binding Site Group Ltd). If either test gave abnormal results, serum immunofixation electrophoresis was used (Sebia Hydragel Immunofixation PE kit on the Hydrasys system). The presence of a monoclonal protein indicative of a MGUS was defined by an intact immunoglobulin band using immunofixation electrophoresis or an abnormal serum FLC ratio with a corresponding elevation in the concentration of involved FLC isotype (FLC-MGUS). The reference range for the serum FLC ratio in renal disease is 0.37 to 3.1.<sup>23,24</sup> Polyclonal FLC concentrations were determined by combining serum  $\kappa$ FLC and  $\lambda$ FLC concentrations (combined FLC [cFLC]); the reference range was 9.3 to 43.3 mg/L.<sup>17</sup>

### Statistical Analyses

Excluding patients who died, the cohort was prospectively followed up for a median of 68 months (interquartile range [IQR], 52-93 months). The cause of death was that recorded on the death certificate held by the General Register Office. The causes of death were categorized as CVD, infection, cancer, renal failure, or other.

The Kaplan-Meier method was used to analyze quintiles of cFLC levels. Cox proportional hazards regression analysis was used to

examine factors associated with survival times. Those alive at the end of the study period were censored according to their follow-up time. In addition, logistic regression was used to examine factors associated with 1-year survival.

Univariate analyses were performed to the end of the study period and for 1-year survival in relation to the variables collected at baseline. These comprised age, sex, ethnicity, CVD comorbidity (ischemic heart disease, cardiac failure, cerebrovascular disease, and peripheral vascular disease), BP, and the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and serum laboratory variables (albumin, phosphate, calcium, creatinine, cystatin C, hsCRP, eGFR, and serum FLC). Continuous variables with a highly skewed distribution were log transformed before analysis. Indicator variables were used to fit categorical predictor variables.

Those variables with  $P < 0.2$  in a univariate analysis were included in a multivariate analysis. For overall survival, this analysis comprised all independent variables. For CVD, the variable any CVD (not individual diseases) was included to represent one or more CVD comorbidities. For survival at 1 year, ethnicity, diastolic BP, and ACR had a  $P \geq .2$  and were not included in the multivariate analysis. Before the multivariate analysis, the collinearity between the variables was determined; variance inflation factors with a value above 10 were considered as evidence of collinearity. The variables serum creatinine and the abbreviated modification of diet in renal disease estimated glomerular filtration rate (MDRD eGFR) were colinear, and eGFR was included in the multivariate analysis.  $\kappa$ FLC,  $\lambda$ FLC, and cFLC were also colinear; cFLC was included in the multivariate analysis. A backward selection procedure was used to retain variables that were statistically significant by using a significance level of .05.

Continuous variables were compared between groups using the analysis of variance and the Kruskal-Wallis test, as appropriate. Analyses using receiver operating characteristic curves examined the utility of routine laboratory tests for kidney function and serum cFLC for the prediction of death at 1 year. The area-under-the-curve (AUC) values for each variable with the corresponding CI were calculated.

In addition, analyses examined factors associated with individual causes of death.

Cox proportional hazards regression models were again used for the analysis. Patients who did not die were censored at the time of last follow-up, whereas those who died of a different cause were censored at the time of death.

Analysis was performed using SPSS (version 21, IBM Corporation) and Stata Statistical Software (version 12.1, Stata Corporation).

## RESULTS

Demographic characteristics, laboratory data, and renal diagnoses are given in Table 1. The cohort was predominately white (79% of stated; 656), with a mean age of 60 years; 54% (455) were men. Twenty-one percent of the patients had diabetes as a comorbidity. The patients were distributed according to the CKD stage: stage 1, 2% (17); stage 2, 17% (142); stage 3a, 19% (158); stage 3b, 27% (229); stage 4, 25% (212); stage 5, 8% (70) and not stated 2% (20). The median duration of follow-up for the whole cohort (including deaths) was 63 months (IQR range, 0-93 months),

**TABLE 1. Population Demographic and Baseline Characteristics of 848 Patients With CKD<sup>a,b</sup>**

Age (y)	60±17
Sex: male	54
Ethnicity	
White	79
South Asian	11
African Caribbean	7
Other	3
ACR (mg/mmol)	10 (2-59)
Albumin (g/L)	43±4.42
Calcium (mmol/L)	2.29±0.15
Phosphate (mmol/L)	1.30±0.28
Creatinine (μmol/L)	153 (112-222)
eGFR (mL/min per 1.73 m <sup>2</sup> )	45±27.63
$\kappa$ FLC (mg/L)	27 (16-47)
$\lambda$ FLC (mg/L)	28 (18-44)
cFLC (mg/L)	56 (35-91)
Renal disease	
Glomerulonephritis	39
Pyelonephritis/renal tract calculi	7
Interstitial nephritis	3
Hereditary nephropathies	8
Hypertensive/renovascular	23
Diabetic nephropathy	8
Other	14

<sup>a</sup>ACR = albumin creatinine ratio; cFLC = combined free light chain; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate;  $\kappa$ FLC = kappa free light chain;  $\lambda$ FLC = lambda free light chain.

<sup>b</sup>Values are presented as mean ± SD, No. (percentage), or median (interquartile range).

**TABLE 2. Cox Regression Analysis of Variables Associated With All-Cause Mortality: Univariate Analysis<sup>a,b</sup>**

Variable	Hazard ratio (95% CI)	P value
Age (y) <sup>c</sup>	2.20 (1.90-2.53)	<.001
Sex		
Male	1.76 (1.28-2.43)	.001
Female	1	
Ethnicity		
White	1	.05
South Asian	0.42 (0.22-0.83)	
African Caribbean	0.72 (0.37-1.41)	
Other	0.55 (0.17-1.71)	
CKD stage		
1-2	1	<.001
3a	1.00 (0.38-2.70)	
3b	4.53 (2.14-9.56)	
4	7.37 (3.55-15.30)	
5	9.97 (4.55-21.80)	
ACE inhibitors		
No	1	.05
Yes	0.73 (0.53-1.00)	
IHD		
No	1	<.001
Yes	2.60 (1.81-3.74)	
MI/angioplasty		
No	1	.01
Yes	1.94 (1.17-3.20)	
PVD		
No	1	<.001
Yes	3.08 (1.95-4.88)	
CVA		
No	1	<.001
Yes	2.90 (1.73-4.86)	
Cardiovascular disease (any)		
No	1	<.001
Yes	3.54 (2.58-4.85)	
Diabetes		
No	1	<.001
Yes	1.98 (1.43-2.73)	
Systolic BP (mm Hg) <sup>c</sup>	1.15 (1.07-1.23)	<.001
Diastolic BP (mm Hg) <sup>c</sup>	0.79 (0.68-0.92)	.002
ACR (mg/mmol) <sup>d</sup>	1.12 (1.03-1.22)	.01
Albumin (g/L) <sup>e</sup>	0.85 (0.74-0.97)	.02
Calcium (mmol/L)	0.21 (0.09-0.51)	.001
Phosphate (mmol/L)	3.72 (2.24-6.19)	<.001
Creatinine (μmol/L) <sup>d</sup>	3.58 (2.72-4.72)	<.001
MDRD eGFR (mL/min per 1.73 m <sup>2</sup> )	0.64 (0.58-0.71)	<.001
hsCRP (mg/L) <sup>d</sup>	1.44 (1.27-1.62)	<.001
Cystatin C (mg/L)	1.69 (1.53-1.87)	<.001
cFLC (mg/L) <sup>d</sup>	3.21 (2.56-4.02)	<.001
κFLC (mg/L) <sup>d</sup>	3.06 (2.40-3.80)	<.001
λFLC (mg/L) <sup>d</sup>	3.00 (2.40-3.76)	<.001

Continued

**TABLE 2. Continued**

Variable	Hazard ratio (95% CI)	P value
Renal disease		
Glomerulonephritis	1	<.001
Pyelonephritis/renal tract calculi	1.81 (0.85-3.81)	
Interstitial nephritis	2.55 (0.99-6.60)	
Hereditary nephropathies	1.23 (0.54-2.82)	
Hypertensive/ renovascular	4.29 (2.76-6.66)	
Diabetic nephropathy	4.35 (2.48-7.63)	
Other	3.47 (2.11-5.72)	

<sup>a</sup>ACE = angiotensin-converting enzyme; ACR = albumin creatinine ratio; BP = blood pressure; cFLC = combined free light chain; CKD = chronic kidney disease; CVA = cerebrovascular accident; eGFR = estimated glomerular filtration rate; hsCRP = high-sensitivity C reactive protein; IHD = ischemic heart disease; κFLC = kappa free light chain; λFLC = lambda free light chain; MDRD = modification of diet in renal disease; MI = myocardial infarction; PVD = peripheral vascular disease.

<sup>b</sup>ACR, systolic BP, and diastolic BP values presented are the median of 3 clinic appointments.

<sup>c</sup>Analyzed in 10-unit increases.

<sup>d</sup>Analyzed on a log scale.

<sup>e</sup>Analyzed in 5-unit increases.

whereas the median duration for the patients who did not die was 68 months (IQR range, 52-93 months). In total, there were 50,675 patient-months available for analysis. At the end of follow-up, 20% (167) of the patients had died.

### Serum FLC Levels and Survival


The median serum polyclonal FLC levels were as follows: κFLC, 27 mg/L (IQR, 16-47 mg/L); λFLC, 28 mg/L (IQR, 18-44 mg/L); cFLC, 56 mg/L (IQR, 35-91 mg/L) (Table 1). The cFLC levels were inversely related to eGFRs (Kruskal-Wallis test,  $P < .001$ ). Univariate Cox regression analysis indicated that a number of demographic, clinical, and laboratory variables were associated with survival (Table 2). Higher levels of serum FLC, both as single isotypes and as cFLC, were associated with reduced survival; a 1-unit increase in cFLC (on the log scale) was associated with a 3-fold increased risk of death (hazard ratio [HR], 3.21; 95% CI, 2.56-4.02). This finding was true for both κFLC (HR, 3.06; 95% CI, 2.40-3.80) and λFLC (HR, 3.00; 95% CI, 2.40-3.76) isotypes (Table 2). A Kaplan-Meier survival plot for the cohort by quintiles of cFLC levels is shown in the Figure.

Because there was marked colinearity between the level of the 2 FLC isotypes and cFLC level, only cFLC was included in the multivariate analysis. Similarly, creatinine was excluded from the multivariate analysis and eGFR retained. Multivariate analysis indicated that cFLC, age, ethnicity, cardiovascular comorbidity, and hsCRP were all independently associated with mortality (Table 3). Of these variables, cFLC had the highest HR for death (HR, 2.71; 95% CI, 1.98-3.70). All other variables, including eGFR and ACR, were not independent significant predictors of mortality.

Importantly, cFLC remained significantly associated when deaths within the first year of follow-up were analyzed (odds ratio [OR], 3.70 for a 1-unit increase on the log scale; 95% CI, 2.14-6.41;  $P<.001$ ). The multivariate analysis of significant variables found age (OR, 1.75 for a 10-year increase; 95% CI, 1.19-2.56;  $P=.005$ ), CVD (OR, 3.14; 95% CI, 1.34-7.37;  $P=.008$ ), cFLC (OR, 2.20; 95% CI, 1.03-4.75;  $P=.04$ ), and hsCRP (OR, 1.50; 95% CI, 1.10-2.02;  $P=.009$ ) to be independently predictive of mortality within 1 year. Furthermore, the AUC statistic was greater for the prediction of survival when using this combination of variables (AUC statistic, 0.86) compared with any of the classically measured renal markers (Table 4).

### Causes of Death

The causes of death were identified in 164 of 167 patients who died. The major causes of death (where reported) were CVD (39%), infections (27%), cancers (18%), and renal failure (11%). Eight percent of the patients died of other causes. The proportion of individuals who died progressively increased with higher FLC quintiles (3.7%, 10.9%, 14.1%, 24.1%, and 43.8%); however, the distribution of causes of death was not significantly different between the FLC quintiles: CVD (50.0%, 21.1%, 33.3%, 41.5%, and 43.2%), infection (16.7%, 31.6%, 33.3%, 31.7%, and 23.0%), and cancer (16.7%, 36.8%, 16.7%, 4.9%, and 20.3%) ( $\chi^2$  test,  $P=.245$ ). Univariate Cox regression analysis found a significant association between cFLC and each cause of death (CVD HR, 3.65; infection HR, 3.00; renal HR, 3.91; cancer HR, 2.53, all  $P<.001$  for a 1-unit increase on the log scale). Multivariate analysis found that cFLC independently predicted deaths from CVD (HR, 2.97;  $P<.001$ ), cancer (HR, 2.06;



**FIGURE.** Survival by quintiles of combined FLC levels. Higher combined FLC levels were associated with a significantly reduced survival ( $P<.001$ ).

$P=.02$ ), and infection (HR, 1.84;  $P=.03$ ); in addition, age was an independent risk factor for death from all 4 causes (CVD HR, 1.68,  $P<.001$ ; infection HR, 2.11,  $P<.001$ ; renal HR, 2.85,  $P<.001$ ; cancer HR, 1.76,  $P=.001$  for a 10-year increase on the log scale); history of CVD was associated with cardiovascular mortality (HR, 2.08;  $P=.005$ ); hsCRP (HR, 1.32;  $P=.02$ ) and male sex (HR, 2.70;  $P=.02$ ) were independently associated with deaths from infection; cystatin C (HR 1.70;  $P=.04$ ) and systolic BP (HR 1.30;  $P=.02$ ) were predictive of renal mortality.

### DISCUSSION

The objective of this study was to determine whether serum levels of polyclonal immunoglobulin cFLC can stratify people with CKD for the risk of mortality. In this cohort of 848 individuals with CKD, cFLC predicted mortality independently of all other factors studied, including kidney function and hsCRP.

Increasing serum levels of both  $\kappa$ FLC and  $\lambda$ FLC and the summation of the 2 isotypes (cFLC) predicted increased mortality. As anticipated, the colinearity between these 3 variables



**TABLE 3. Cox Regression Analysis of Variables Associated With All-Cause Mortality: Multivariate Analysis<sup>a</sup>**

Variable	Hazard ratio (95% CI)	P value
Age (y) <sup>b</sup>	1.79 (1.52-2.10)	<.001
Ethnicity		
White	1	
South Asian	0.33 (0.14-0.64)	
African Caribbean	0.72 (0.32-1.67)	.02
Other	0.73 (0.24-2.42)	
Cardiovascular disease (any)		
No	1	
Yes	1.59 (1.09-2.31)	.02
cFLC (mg/L) <sup>c</sup>	2.71 (1.98-3.70)	<.001
hsCRP (mg/L) <sup>c</sup>	1.13 (1.00-1.28)	.04

<sup>a</sup>cFLC = combined free light chain; hsCRP = high-sensitivity C reactive protein.

<sup>b</sup>Analyzed in 10-unit increases.

<sup>c</sup>Analyzed on a log scale.

was high; therefore, in the multivariate analysis, only cFLC was evaluated.

To date, this is the largest study on associations between polyclonal FLC and clinical outcomes in patients with CKD. In a recent study on associations between monoclonal and polyclonal FLC in patients with CKD, we found an overall association between  $\lambda$ FLC and survival in a multivariable analysis of a range of clinical variables, including markers of cardiac injury (N-terminal prohormone of brain natriuretic peptide and troponin). The cohort was smaller, had advanced CKD (median eGFR, 21.9 mL/min per 1.73 m<sup>2</sup>), and had high comorbidity as compared with those measured in the present study.<sup>16</sup>

**TABLE 4. AUC Analysis of Variables Associated With Renal Function or Significant by Multivariate Analysis and Survival at 1 y<sup>a</sup>**

Variable	AUC (95% CI)
MDRD eGFR	0.67 (0.60-0.75)
ACR	0.54 (0.45-0.63)
Cystatin C	0.74 (0.67-0.82)
cFLC	0.74 (0.67-0.82)
Multivariate regression model <sup>b</sup>	0.86 (0.79-0.93)

<sup>a</sup>AUC = area under the curve; ACR = albumin creatinine ratio; cFLC = combined free light chain; eGFR = estimated glomerular filtration rate; MDRD = modification of diet in renal disease.

<sup>b</sup>Multivariate regression model consisting of age, cardiovascular disease, FLC, and hsCRP.

In the general population, there are 2 large cohorts with data available on the association between polyclonal FLC and outcomes. First, Dispenzieri et al<sup>17</sup> analyzed outcomes in approximately 16,000 people included in the Olmsted county cohort and found, by using multivariable analysis, an independent mortality risk associated with high polyclonal cFLC levels. Second, the German Heinz Nixdorf Recall health-screening study found an independent association between polyclonal FLC and survival in 4350 people.<sup>25</sup> In addition, a recent study has used data from patients who have undergone routine hematological assessments for a monoclonal gammopathy; in patients with a monoclonal gammopathy excluded, elevated cFLC levels were independently associated with increased mortality.<sup>12</sup>

Serum levels of cFLC are representative of 2 factors: (1) their production rates and (2) their serum half-lives. The basic immunoglobulin molecule consists of 2 heavy chains and 2 light chains that are linked by disulfide bonds. The production of FLC is related to an excess production of light chains over heavy chains, such that excess FLCs are released into the circulation in health at an estimated rate of 500 mg/d. Although any cell derived from the B-cell lineage can produce FLC, most of the FLCs will be released from mature plasma cells. The production rate of FLC therefore represents the activity of the adaptive immune system.

The second effect on the serum levels of FLC is serum half-life, which is predominantly affected by kidney function.<sup>23</sup> Both isotypes of FLC are molecules that are cleared by glomerular filtration, and so as kidney function levels (GFR) decrease, serum FLC levels increase. There was a close association between the absolute serum FLC levels and kidney function, and so cFLC levels increased with the decreasing levels of kidney function. Serum cFLC levels were predictive of overall survival in both univariate and multivariate analyses. A further evaluation of the cause of death established that cFLC levels were independently associated with deaths from CVD and infection. Moreover, the risk associated with cFLC was independent of eGFR and ACR.

The association described herein between serum levels of cFLC and mortality identifies FLC as a biomarker of potential clinical utility.

However, FLC could also be mechanistically involved in the poor outcomes of this population, although the data for this are currently sparse. Although the pathways by which monoclonal FLC cause direct tissue injury in diseases such as multiple myeloma and amyloid light chain amyloidosis are well described,<sup>26,27</sup> there is less evidence to date for polyclonal FLC, with studies limited to in vitro experiments establishing a role of polyclonal FLC in the inhibition of leukocyte phagocytosis and in chronic inflammation.<sup>28</sup>

## CONCLUSION

This study reports a potential role of polyclonal cFLC to act as a biomarker by which patients with CKD can be risk stratified for mortality. The principal limitation of the study is the cross-sectional design and short follow-up. Further studies are required to identify how the association between serum FLC levels and mortality can be used to improve outcomes for people with CKD and the mechanistic basis for this association.

**Abbreviations and Acronyms:** ACR = albumin creatinine ratio; AUC = area under the curve; BP = blood pressure; cFLC = combined free light chain; CKD = chronic kidney disease; CVD = cardiovascular disease; eGFR = estimated glomerular filtration rate; FLC = free light chain; hsCRP = high-sensitivity C-reactive protein; HR = hazard ratio; IQR = interquartile range; κFLC = kappa free light chain; λFLC = lambda free light chain; MGUS = monoclonal gammopathy of undetermined significance

**Grant Support:** Research and travel funding were provided by the Binding Site Group Ltd. Research funding for Drs Jesky and Stringer was provided by the JABBS Foundation.

**Potential Competing Interests:** Dr Burmeister is an employee of the Binding Site Group Ltd. Dr Harding is the director of R&D at the Binding Site Group Ltd.

**Correspondence:** Address to Paul Cockwell, PhD, Department of Renal Medicine, Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB, United Kingdom (paul.cockwell@uhb.nhs.uk).

## REFERENCES

- James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease [published correction appears in *Lancet*. 2010;376(9736):162]. *Lancet*. 2010;375(9722):1296-1309.
- Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. *JAMA*. 2007;298(17):2038-2047.
- Collins AJ, Chen SC, Gilbertson DT, Foley RN. CKD surveillance using administrative data: impact on the health care system. *Am J Kidney Dis*. 2009;53(3, suppl 3):S27-S36.
- Kerr M, Bray B, Medcalf J, O'Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. *Nephrol Dial Transplant*. 2012;27(suppl 3):iii73-iii80.
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [published correction appears in *N Engl J Med*. 2008;18(4):4]. *N Engl J Med*. 2004;351(13):1296-1305.
- Matsushita K, van der Velde M, Astor BC, et al; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet*. 2010;375(9731):2073-2081.
- Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. *Adv Chronic Kidney Dis*. 2006;13(3):199-204.
- Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. *Lancet*. 1999;354(9173):93-99.
- Yilmaz MI, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P. Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences. *Clin Nephrol*. 2007;68(1):1-9.
- Dispenzieri A, Kyle R, Merlini G, et al; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia*. 2009;23(2):215-224.
- Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. *Leukemia*. 2006;20(9):1467-1473.
- Anandram S, Assi LK, Lovatt T, et al. Elevated, combined serum free light chain levels and increased mortality: a 5-year follow-up, UK study. *J Clin Pathol*. 2012;65(11):1036-1042.
- Hutchison CA, Landgren O. Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. *Clin Chem*. 2011;57(10):1387-1389.
- Tsai HT, Caporaso NE, Kyle RA, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. *Blood*. 2009;114(24):4928-4932.
- Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. *J Clin Oncol*. 2010;28(5):773-779.
- Haynes R, Hutchison CA, Emberson J, et al. Serum free light chains and the risk of ESRD and death in CKD. *Clin J Am Soc Nephrol*. 2011;6(12):2829-2837.
- Dispenzieri A, Katzmann JA, Kyle RA, et al. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. *Mayo Clin Proc*. 2012;87(6):517-523.
- Aggarwal R, Sequeira W, Kokebie R, et al. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. *Arthritis Care Res (Hoboken)*. 2011;63(6):891-898.
- Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2005;67(6):2089-2100.
- Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ III. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. *Mayo Clin Proc*. 2004;79(7):859-866.
- Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2002;346(8):564-569.
- Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study [published correction appears in *Lancet*. 2010;376(9738):332]. *Lancet*. 2010;375(9727):1721-1728.



23. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. *Clin J Am Soc Nephrol*. 2008;3(6):1684-1690.
24. Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. *BMC Nephrol*. 2008;9:11.
25. Durig J, Eisele L, Huttman A, Duhrsen U, Fuhrer A, Kieruzel S. Polyclonal free light chain evaluation and mortality in the German Heinz Nixdorf Recall Study. *Hematol Rep*. 2010;2(s2):13.
26. Sanders PW, Herrera GA, Kirk KA, Old CW, Galla JH. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypic immunoglobulin light chain deposition. *Lab Invest*. 1991;64(4):527-537.
27. Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. *Hematology Am Soc Hematol Educ Program*. 2010;2010:287-294.
28. Cohen G, Hörl WH. Free immunoglobulin light chains as a risk factor in renal and extrarenal complications. *Semin Dial*. 2009; 22(4):369-372.